Phase I and pharmacologic evaluation of nafazatrom in patients with cancer
- 1 March 1984
- journal article
- Published by Springer Nature in Investigational New Drugs
- Vol. 2 (1) , 13-17
- https://doi.org/10.1007/bf00173782
Abstract
Nafazatrom was evaluated in escalating daily oral doses ranging from 0.25 to 8.0 g/m2 without producing significant toxicities. Malabsorption proved dose limiting at 8.0 g/m2 as a single daily dose, but splitting the same total dose into two or four doses circumvented this problem. Doses of 2.0 g/m2 at 6-h intervals or 4.0 g/m2 every 12 h are reasonable for Phase II and adjuvant trials. Pharmacologic evaluation of nafazatrom confirmed malabsorption at the highest single daily dose level tested and suggests that absorption was impaired in patients with extensive liver metastases.Keywords
This publication has 6 references indexed in Scilit:
- High-performance liquid chromatographic determination of nafazatrom in human plasma using fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Nafazatrom (bay g 6575) inhibition of tumor cell lipoxygenase activity and cellular proliferationFEBS Letters, 1982
- Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).1982
- Prostacyclin: A Potent Antimetastatic AgentScience, 1981
- STIMULATION OF PROSTACYCLIN RELEASE FROM VESSEL WALL BY BAY g 6575, AN ANTITHROMBOTIC COMPOUNDThe Lancet, 1979
- The antithrombotic activity of BAY g 6575.1979